Identification of two rare and novel large deletions in ITGB4 gene causing epidermolysis bullosa with pyloric atresia Articles uri icon

authors

  • MENCIA RODRIGUEZ, ANGELES
  • GARCIA DIEZ, MARTA
  • GARCÍA, EVA
  • GONZALEZ LLAMES, SARA
  • CHARLESWORTH, ALEXANDRA
  • DE LUCAS LAGUNA, RAUL
  • VICENTE, ASUNCION
  • TRUJILLO-TIEBAS, MARIA JOSE
  • COTO, PABLO
  • COSTA, MARTA
  • VERA, ÁNGEL
  • LÓPEZ PESTANA, ARANTXA
  • MURILLAS ANGOITI, RODOLFO
  • MENEGUZZI, GUERRINO
  • JORCANO NOVAL, JOSE LUIS
  • CONTI, CLAUDIO JORGE
  • ESCAMEZ TOLEDANO, MARIA JOSE
  • RIO NECHAEVSKY, MARCELA ANDREA DEL

publication date

  • April 2016

start page

  • 269

end page

  • 274

issue

  • 4

volume

  • 25

International Standard Serial Number (ISSN)

  • 0906-6705

Electronic International Standard Serial Number (EISSN)

  • 1600-0625

abstract

  • Epidermolysis bullosa with pyloric atresia (EB-PA) is a rare autosomal recessive hereditary disease with a variable prognosis from lethal to very mild. EB-PA is classified into Simplex form (EBS-PA: OMIM #612138) and Junctional form (JEB-PA: OMIM #226730), and it is caused by mutations in ITGA6, ITGB4 and PLEC genes. We report the analysis of six patients with EB-PA, including two dizygotic twins. Skin immunofluorescence epitope mapping was performed followed by PCR and direct sequencing of the ITGB4 gene. Two of the patients presented with non-lethal EB-PA associated with missense ITGB4 gene mutations. For the other four, early postnatal demise was associated with complete lack of 4 integrin due to a variety of ITGB4 novel mutations (2 large deletions, 1 splice-site mutation and 3 missense mutations). One of the deletions spanned 278 bp, being one of the largest reported to date for this gene. Remarkably, we also found for the first time a founder effect for one novel mutation in the ITGB4 gene. We have identified 6 novel mutations in the ITGB4 gene to be added to the mutation database. Our results reveal genotype-phenotype correlations that contribute to the molecular understanding of this heterogeneous disease, a pivotal issue for prognosis and for the development of novel evidence-based therapeutic options for EB management.

keywords

  • epidermolysis bullosa; genodermatoses; inherited skin diseases; itgb4 mutations; pyloric atresia; aplasia-cutis-congenita; integrin beta-4 subunit; cytoplasmic domain; simplex; plectin; lethal; involvement; sequences; variants